NCT03702140

Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Shinshu University · Academic / Other
• Sex: All
• Age: 20 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients: 1. The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months. 2. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months. 3. The administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.

Conditions

• Osteoporosis

Interventions

Type	Name	Description
DRUG	"Teriparatide", "Forteo® or Teribon"	To examine the effects of terimaratide less than 6 months in osteoporosis

Timeline

• Start date: 2018-10-09
• Primary completion: 2023-10-08
• Completion: 2025-10-08
• First posted: 2018-10-10
• Last updated: 2021-09-21

Locations

1 site across 1 country: Japan